Re: Threshold Pharmaceuticals, Inc (THLD): Opiniones
http://www.thelifesciencesreport.com/pub/co/4663
"Philippa Gardner, Edison Investment Research (11/18/14) "Additional interim data from the ongoing Phase 1/2 investigator-led trial of Threshold Pharmaceuticals Inc.'s TH-302 in glioblastoma (GBM) have been reported at the Society for Neuro-Oncology conference. Based on the early signs of efficacy observed. . .plans for an investigator-led, two-center Phase 2 trial have now been confirmed, supported by an FDA grant. GBM could be an indication eligible for accelerated development, given the unmet medical need. . .TH-302 has been partnered with Merck KGaA in a $525M deal and has potential across a broad range of tumors, with Phase 3 trials in both soft tissue sarcoma and pancreatic cancer ongoing."